PDEX
Posted by: Georgia Retina in
Research Title: Triple Therapy — PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration Sponsor: Bay Area Retina Associates Principal Investigator: Atul Sharma, M.D. Description: The purpose of this study is to compare triple therapy using Photodynamic therapy, intravitreal Dexamethasone and intravitreal Ranibizumab injections versus monotherapy with intravitreal Ranibizumab alone for the treatment of…
Read More
Regeneron R2176-3-AMD-1417 CAPELLA
Posted by: Georgia Retina in
Research Title: A Phase 2, Double-Masked, Randomized, Controlled, Multiple-Dose, Regimen-Ranging Study of the Efficacy and Safety of Intravitreal REGN2176-3 in Patients With Neovascular Age-Related Macular Degeneration. Sponsor: Regeneron Pharmaceuticals Principal Investigator: Michael Jacobson, M.D. Description: The primary objective of the study is to explore the effect of REGN2176-3 on the Early Treatment Diabetic Retinopathy Scale (ETDRS) best-corrected visual acuity…
Read More Regeneron R910-3-AMD-1517 ONYX
Posted by: Georgia Retina in
Research Title: A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Realted Macular Degeneration. Sponsor: Regeneron Pharmaceuticals Principal Investigator: Michael Jacobson, M.D. Description: The primary objective of the study is to compare the efficacy of intravitreal (IVT)-administered REGN910-3 compared to intravitreal aflibercept injection (IAI). Start…
Read More Regeneron R910-3-DME-1518 RUBY
Posted by: Georgia Retina in
Research Title: A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema. Sponsor: Regeneron Pharmaceuticals Principal Investigator: Michael Jacobson, M.D. Description: The primary objective of the study is to compare the efficacy of intravitreal (IVT)-administered REGN910-3 compared to intravitreal aflibercept injection (IAI) in improving…
Read More Regeneron VGFTe-OD-1411 PANORAMA
Posted by: Georgia Retina in
Research Title: Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR) Sponsor: Regeneron Pharmaceuticals Principal Investigator: Michael Jacobson, M.D. Description: The primary objective of the study is to assess the efficacy of intravitreal (IVT) aflibercept compared to sham treatment in the improvement of moderately severe to…
Read More Genentech GR39821
Posted by: Georgia Retina in
Research Title: A Phase I, Multicenter, Open-Label, Single-Dose, Dose-Escalation, and Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7171009 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration. Sponsor: Genentech, Inc. Principal Investigator: Robert Stoltz, M.D., Ph.D. Description: This Phase 1, open-label, multicenter study will investigate the safety and tolerability of RO7171009 following…
Read More Graybug GBV-102-002 Altissimo
Posted by: Georgia Retina in
Research Title: A Phase 2b Multicenter Dose-Ranging Study Evaluating the Safety and Efficacy of Sunitinib Malate Depot Formulation (GB-102) Compared to Aflibercept in Subjects With Neovascular (Wet) Age-related Macular Degeneration (ALTISSIMO Study) Sponsor: Graybug Vision Principal Investigator: Atul Sharma, M.D. Description: Phase 2b, multicenter, visual examiner-masked, randomized active-controlled, parallel-arm design study to evaluate the safety and duration of the…
Read More HORIZON FVF3426g
Posted by: Georgia Retina in
Research Title: An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVO Sponsor: Genentech Principal Investigator: Jay Stallman, M.D. Description: This is an open-label, multicenter, extension study of intravitreally administered ranibizumab in subjects with primary or recurrent CNV secondary to AMD who have completed…
Read More AART C-02-60
Posted by: Georgia Retina in
Research Title: Anecortave Acetate Risk-Reduction Trial (AART) Sponsor: Allergan Principal Investigator: Atul Sharma, M.D. Description: A 48-month study of posterior juxtascleral administrations of Anecortave Acetate 15 or 30 mg or sham administration every 6 months. Start Date: March 2006 Recruitment: Completed Project Personnel: Leslie Marcus, CCRC Location(s): Riverdale; 155 Medical Way, Suite E, Riverdale, GA 30274
Read More Allergan 1771-201-008 MAPLE
Posted by: Georgia Retina in
Research Title: Evaluating Abicipar for Safety and Treatment Effect in Patients With Neovascular Age-related Macular Degeneration (AMD) Sponsor: Allergan Principal Investigator: Robert Stoltz, M.D., Ph.D. Description: The objective of this study is to evaluate abicipar for safety and treatment effect in patients with neovascular Age-related Macular Degeneration (AMD). Start Date: June 2018 Recruitment: Enrolling Project Personnel: Leslie Marcus, CCRC; Caitlin Harrison, CCRC,…
Read More 
